The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -29.16 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -3.52 — no flag raisedOK
- Earnings quality 88/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BIOMERICA INC reports it. History and quarterly detail are in the app.
- Clinical Lab$3.2M
- Contract Manufacturing$1.1M
- Over The Counte$1.0M
- Physicians Office$11K
Leadership changes
From BIOMERICA INC's own filings, the day they're filed.
- Cathy Coste · member · departureeff. 2025-06-04
- Jack Kenny · director · appointment
- Nasdaq Rule · director · appointment
Latest filings
- 8-K · Company announcement2026-06-04
- 10-Q · Quarterly report2026-04-13
- 10-Q · Quarterly report2026-01-14
- 8-K · Company announcement2025-12-16
- DEF 14A · Annual proxy (pay & governance)2025-10-20
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BIOMERICA INC, every answer cited🔒
- The Intelligence Brief — added when BIOMERICA INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.